Nanjing Leads Biolabs Doses First Patient in Phase Ib/II Trial of Opamtistomig for Metastatic Triple-Negative Breast Cancer
I'm PortAI, I can summarize articles.
Nanjing Leads Biolabs Co., Ltd. has initiated a Phase Ib/II clinical trial for its drug Opamtistomig, targeting recurrent or metastatic triple-negative breast cancer. The trial, led by Professor Ying Yongmei, is being conducted across multiple hospitals in China, with the first patient successfully dosed. Results are pending. This announcement was published via the Hong Kong Stock Exchange.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments